Levi & Korsinsky announces it has commenced an investigation of Pernix Therapeutics Holdings, Inc. (NasdaqGM: PTX) concerning possible breaches of fiduciary duty by its Board of Directors. In particular, we determined that since February 5, 2014, the Company granted the CEO approximately 1,500,000 in-the-money options, valued at approximately $2 million, in violation of Company’s shareholder-approved executive compensation plan. We are investigating an action seeking to force the Company to rescind the improper option grants. To receive more information regarding the investigation of Pernix Therapeutics please fill out the form below.
To receive more information, please fill out the form.